CSPC Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
CSPC Pharmaceutical Group Limited (HKG:1093) defied analyst predictions to release its half-year results, which were ahead of market expectations. Statutory earnings performance was extremely strong, with revenue of CN¥19b beating expectations by 40% and earnings per share (EPS) of CN¥0.46, an impressive 49%ahead of expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Taking into account the latest results, the consensus forecast from CSPC Pharmaceutical Group's 21 analysts is for revenues of CN¥33.2b in 2026. This reflects a modest 6.0% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to expand 19% to CN¥0.77. Yet prior to the latest earnings, the analysts had been anticipated revenues of CN¥31.0b and earnings per share (EPS) of CN¥0.64 in 2026. So it seems there's been a definite increase in optimism about CSPC Pharmaceutical Group's future following the latest results, with a massive increase in the earnings per share forecasts in particular.
See our latest analysis for CSPC Pharmaceutical Group
It will come as no surprise to learn that the analysts have increased their price target for CSPC Pharmaceutical Group 5.1% to HK$12.31on the back of these upgrades. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on CSPC Pharmaceutical Group, with the most bullish analyst valuing it at HK$19.36 and the most bearish at HK$7.20 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the CSPC Pharmaceutical Group's past performance and to peers in the same industry. One thing stands out from these estimates, which is that CSPC Pharmaceutical Group is forecast to grow faster in the future than it has in the past, with revenues expected to display 12% annualised growth until the end of 2026. If achieved, this would be a much better result than the 0.7% annual decline over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 10.0% annually. Not only are CSPC Pharmaceutical Group's revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards CSPC Pharmaceutical Group following these results. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for CSPC Pharmaceutical Group going out to 2028, and you can see them free on our platform here..
That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with CSPC Pharmaceutical Group (at least 1 which is concerning) , and understanding these should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.